{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:36:16Z","timestamp":1793147776163,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41375-026-02986-3","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:23:21Z","timestamp":1779794601000},"page":"1516-1526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Artificial intelligence-enhancement of flow cytometry data accelerates the identification of measurable residual chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6431-2666","authenticated-orcid":false,"given":"April","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jansen N.","family":"Seheult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-4293","authenticated-orcid":false,"given":"Min","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa E.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5658-936X","authenticated-orcid":false,"given":"Mathew J.","family":"Weybright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Otteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-4485","authenticated-orcid":false,"given":"Horatiu","family":"Olteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-6157","authenticated-orcid":false,"given":"Pedro","family":"Horna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2986_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","volume":"16","author":"F Bosch","year":"2019","unstructured":"Bosch F, Dalla-Favera R. Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol. 2019;16:684\u2013701.","journal-title":"Nat Rev Clin Oncol"},{"key":"2986_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"2986_CR3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","volume":"15","author":"JA Burger","year":"2018","unstructured":"Burger JA, O\u2019Brien S. Evolution of CLL treatment: from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15:510\u201327.","journal-title":"Nat Rev Clin Oncol"},{"key":"2986_CR4","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"2986_CR5","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S Bottcher","year":"2012","unstructured":"Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980\u20138.","journal-title":"J Clin Oncol"},{"key":"2986_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"N Engl J Med"},{"key":"2986_CR7","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","volume":"123","author":"P Strati","year":"2014","unstructured":"Strati P, Keating MJ, O\u2019Brien SM, Burger J, Ferrajoli A, Jain N, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123:3727\u201332.","journal-title":"Blood"},{"key":"2986_CR8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","volume":"131","author":"N Dimier","year":"2018","unstructured":"Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018;131:955\u201362.","journal-title":"Blood"},{"key":"2986_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood-2015-08-634816","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood. 2016;127:279\u201386.","journal-title":"Blood"},{"key":"2986_CR10","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739\u201354.","journal-title":"N Engl J Med"},{"key":"2986_CR11","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1182\/blood.2024024631","volume":"144","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924\u201335.","journal-title":"Blood"},{"key":"2986_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1200\/JCO.24.01192","volume":"43","author":"F Simon","year":"2025","unstructured":"Simon F, Ligtvoet R, Robrecht S, Cramer P, Kutsch N, F\u00fcrstenau M, et al. End point surrogacy in first-line chronic lymphocytic leukemia. J Clin Oncol. 2025;43:381\u201391.","journal-title":"J Clin Oncol"},{"key":"2986_CR13","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/blood.2021013435","volume":"138","author":"C Moreno","year":"2021","unstructured":"Moreno C, Mora A. MRD in CLL: some answers, many questions. Blood. 2021;138:2746\u20137.","journal-title":"Blood"},{"key":"2986_CR14","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: chronic lymphocytic leukemia\/small lymphocytic lymphoma. Version 2.2026. 2026. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf. Accessed December 22, 2026."},{"key":"2986_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/bloodadvances.2025016126","volume":"10","author":"JN Seheult","year":"2026","unstructured":"Seheult JN, Otteson GE, Timm MM, Weybright MJ, Shi M, Olteanu H, et al. Artificial intelligence accelerates the interpretation of measurable residual B lymphoblastic leukemia by flow cytometry. Blood Adv. 2026;10:58\u201369.","journal-title":"Blood Adv"},{"key":"2986_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/cyto.a.24670","volume":"103","author":"J Meskas","year":"2023","unstructured":"Meskas J, Yokosawa D, Wang S, Segat GC, Brinkman RR. flowCut: an R package for automated removal of outlier events and flagging of files based on time versus fluorescence analysis. Cytom A. 2023;103:71\u201381.","journal-title":"Cytom A"},{"key":"2986_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.21105\/joss.00861","volume":"3","author":"L McInnes","year":"2018","unstructured":"McInnes L, Healy J, Saul N, Gro\u00dfberger L. UMAP: uniform manifold approximation and projection. J Open Source Softw. 2018;3:861.","journal-title":"J Open Source Softw"},{"key":"2986_CR18","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1093\/bioinformatics\/btaa042","volume":"36","author":"SV Stassen","year":"2020","unstructured":"Stassen SV, Siu DMD, Lee KCM, Ho JWK, So HKH, Tsia KK. PARC: ultrafast and accurate clustering of phenotypic data of millions of single cells. Bioinformatics. 2020;36:2778\u201386.","journal-title":"Bioinformatics"},{"key":"2986_CR19","doi-asserted-by":"crossref","unstructured":"Salama ME, Otteson GE, Camp JJ, Seheult JN, Jevremovic D, Holmes DR 3rd, et al. Artificial intelligence enhances diagnostic flow cytometry workflow in the detection of minimal residual disease of chronic lymphocytic leukemia. Cancers (Basel) 2022;14:2537.","DOI":"10.3390\/cancers14102537"},{"key":"2986_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/leu.2012.216","volume":"27","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013;27:142\u20139.","journal-title":"Leukemia"},{"key":"2986_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","volume":"129","author":"P Theunissen","year":"2017","unstructured":"Theunissen P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, Gaipa G, Bartels M, et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. Blood. 2017;129:347\u201357.","journal-title":"Blood"},{"key":"2986_CR22","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986\u20132010.","journal-title":"Leukemia"},{"key":"2986_CR23","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/cyto.b.21953","volume":"100","author":"JM Goshaw","year":"2021","unstructured":"Goshaw JM, Gao Q, Wardrope J, Dogan A, Roshal M. 14-color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL\/SLL. Cytom B Clin Cytom. 2021;100:509\u201318.","journal-title":"Cytom B Clin Cytom"},{"key":"2986_CR24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/bjh.18802","volume":"202","author":"PC Nguyen","year":"2023","unstructured":"Nguyen PC, Nguyen V, Baldwin K, Kankanige Y, Blombery P, Came N, et al. Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia. Br J Haematol. 2023;202:760\u201370.","journal-title":"Br J Haematol"},{"key":"2986_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cyto.b.22116","volume":"106","author":"A Bazinet","year":"2024","unstructured":"Bazinet A, Wang A, Li X, Jia F, Mo H, Wang W, et al. Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow. Cytom B Clin Cytom. 2024;106:264\u201371.","journal-title":"Cytom B Clin Cytom"},{"key":"2986_CR26","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/ajh.27604","volume":"100","author":"R Engelmann","year":"2025","unstructured":"Engelmann R, Flores-Montero J, Schilperoord-Vermeulen J, Ritgen M, Hengeveld PJ, Kohlscheen S, et al. Novel flow cytometric antibody panel and dedicated analysis algorithm for automated fully standardized minimal residual disease detection in chronic lymphocytic leukemia. Am J Hematol. 2025;100:724\u20138.","journal-title":"Am J Hematol"},{"key":"2986_CR27","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.3390\/cancers17101688","volume":"17","author":"JN Seheult","year":"2025","unstructured":"Seheult JN, Otteson GE, Weybright MJ, Timm MM, Han W, Jevremovic D, et al. Clinical validation and post-implementation performance monitoring of a neural network-assisted approach for detecting chronic lymphocytic leukemia minimal residual disease by flow cytometry. Cancers (Basel). 2025;17:1688.","journal-title":"Cancers (Basel)"},{"key":"2986_CR28","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"AC Rawstron","year":"2007","unstructured":"Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956\u201364.","journal-title":"Leukemia"},{"key":"2986_CR29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/leu.2015.313","volume":"30","author":"AC Rawstron","year":"2016","unstructured":"Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30:929\u201336.","journal-title":"Leukemia"},{"key":"2986_CR30","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/bjh.12887","volume":"166","author":"S Raponi","year":"2014","unstructured":"Raponi S, Della Starza I, De Propris MS, Del Giudice I, Mauro FR, Marinelli M, et al. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients: a comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol. 2014;166:360\u20138.","journal-title":"Br J Haematol"},{"key":"2986_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.92","volume":"5","author":"TW Farren","year":"2015","unstructured":"Farren TW, Giustiniani J, Fanous M, Liu F, Macey MG, Wright F, et al. Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia. Blood Cancer J. 2015;5:e273.","journal-title":"Blood Cancer J"},{"key":"2986_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.597730","volume":"10","author":"TW Farren","year":"2020","unstructured":"Farren TW, Sadanand KS, Agrawal SG. Highly sensitive and accurate assessment of minimal residual disease in chronic lymphocytic leukemia using the novel CD160-ROR1 assay. Front Oncol. 2020;10:597730.","journal-title":"Front Oncol"},{"key":"2986_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/cyto.b.22170","volume":"106","author":"X Chen","year":"2024","unstructured":"Chen X, Chen X, Zhao S, Shi Y, Zhang N, Guo Z, et al. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia. Cytom B Clin Cytom. 2024;106:181\u201391.","journal-title":"Cytom B Clin Cytom"},{"key":"2986_CR34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/cyto.b.21875","volume":"98","author":"L Bento","year":"2020","unstructured":"Bento L, Correia R, de Sousa F, Vaz A, Pedro E, Schimidell D, et al. Performance of eight-color dry antibody reagent in the detection of minimal residual disease in chronic lymphocytic leukemia samples. Cytom B Clin Cytom. 2020;98:529\u201335.","journal-title":"Cytom B Clin Cytom"},{"key":"2986_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/ijlh.12149","volume":"36","author":"O Stehlikova","year":"2014","unstructured":"Stehlikova O, Chovancova J, Tichy B, Krejci M, Brychtova Y, Panovska A, et al. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2014;36:165\u201371.","journal-title":"Int J Lab Hematol"},{"key":"2986_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1309\/AJCPBV9ELXC0ECVL","volume":"142","author":"P Challagundla","year":"2014","unstructured":"Challagundla P, Medeiros LJ, Kanagal-Shamanna R, Miranda RN, Jorgensen JL. Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. 2014;142:837\u201344.","journal-title":"Am J Clin Pathol"},{"key":"2986_CR37","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1080\/10428194.2021.1919658","volume":"62","author":"A Bazinet","year":"2021","unstructured":"Bazinet A, Rys RN, Barry A, Greenwood CMT, Young YK, Mendoza A, et al. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia. Leuk Lymphoma. 2021;62:2352\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2986_CR38","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.jid.2023.12.020","volume":"144","author":"JN Seheult","year":"2024","unstructured":"Seheult JN, Weybright MJ, Jevremovic D, Shi M, Olteanu H, Horna P. Computational flow cytometry accurately identifies Sezary cells based on simplified aberrancy and clonality features. J Invest Dermatol. 2024;144:1590\u20139. e3.","journal-title":"J Invest Dermatol"},{"key":"2986_CR39","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1182\/blood-2023-190275","volume":"142","author":"JN Seheult","year":"2023","unstructured":"Seheult JN, Shi M, Olteanu H, Otteson GE, Timm MM, Weybright MJ, et al. Machine learning enhancement of flow cytometry data accelerates the identification of minimal residual acute myeloid leukemia. Blood. 2023;142:4339.","journal-title":"Blood"},{"key":"2986_CR40","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1182\/blood-2024-199901","volume":"144","author":"A Chiu","year":"2024","unstructured":"Chiu A, Seheult JN, Shi M, Jevremovic D, Weybright MJ, Timm MM, et al. Artificial intelligence enhancement of flow cytometry data accelerates the identification of minimal residual chronic lymphocytic leukemia. Blood. 2024;144:1858.","journal-title":"Blood"},{"key":"2986_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/leu.2012.231","volume":"27","author":"B Denys","year":"2013","unstructured":"Denys B, van der Sluijs-Gelling AJ, Homburg C, van der Schoot CE, de Haas V, Philippe J, et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2013;27:635\u201341.","journal-title":"Leukemia"},{"key":"2986_CR42","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3324\/haematol.2014.116707","volume":"100","author":"L Karawajew","year":"2015","unstructured":"Karawajew L, Dworzak M, Ratei R, Rhein P, Gaipa G, Buldini B, et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica. 2015;100:935\u201344.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02986-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02986-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02986-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:48:22Z","timestamp":1782917302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02986-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2986"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02986-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors confirm that all methods were performed in accordance with the relevant institutional guidelines and regulations. This study was reviewed and approved by the Mayo Clinic Institutional Review Board (IRB study #16-009316). The IRB determined that the study posed minimal risk to participants and granted a waiver of the requirement for informed consent in accordance with applicable USA federal regulations. No live vertebrate studies were performed. No identifiable images are included in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}